← Relay Therapeutics, Inc. (RLAY) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Relay Therapeutics, Inc. (RLAY)
Biological Products, (No Diagnostic Substances) · market cap $3.9B · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
1
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Relay Therapeutics (RLAY) is a clinical-stage biotech with 188 employees and a $3.6B market cap, built around its lead asset RLY-2608, a PIK3CA-mutant inhibitor currently in Phase 3. The company carries ~$205M in cash, representing roughly 12 months of runway, against a persistent burn rate averaging ~$300M/year in R&D spend.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| RLY-2608 | Phase 3 | PIK3CA Mutation |
Price & technical context
3-month
-0.9%
6-month
+71.7%
12-month
+254.2%
52-wk range
$5.22–$20.75
vs 50-day MA
-3.2%
vs 200-day MA
+32.5%
Realized vol
65.2%
Max drawdown
-79.0%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for RLAY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.